Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.
Checked against the public recordLast updated Mar 20, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Our Lady of the Lake Hospital
- Interventions being studied
- Other: blood draw; Other: Gene sequencing
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * 18-100 years old * Biologically born female * Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group) * No cancer diagnosis (Arm 2-health control) Exclusion Criteria: * less than 18 years of age * Biologically born male * Incarcerated at the time of participation
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Our Lady of the Lake Regional Medical CenterBaton Rouge, Louisiana
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 20, 2025. Always confirm current availability with the study team.